veterinary medicaments producer · 2017. 1. 27. · biobos respi 2 intranasal 38 biobos respi 3 39...

VETERINARY MEDICAMENTS PRODUCER

1. Canine vaccinesBiocan B 12Biocan C 13Biocan DH + L 14Biocan DHPPi 15Biocan DHPPi + L 16Biocan DHPPi + LR 17Biocan DP 18Biocan L 19Biocan LR 20Biocan M 21Biocan M Plus 22Biocan P 23Biocan Puppy 24Biocan R 25Biocan T 26Borrelym 3 27Biocan NOVEL DHPPi 28Biocan NOVEL DHPPi/L4 29Biocan NOVEL DHPPi/L4R 30Biocan NOVEL Pi/L4 31Biocan NOVEL R 32

2. Ca�le vaccinesBioBos IBR marker in 34BioBos IBR marker live 35BioBos L 36BioBos L(6) 37BioBos Respi 2 intranasal 38BioBos Respi 3 39BioBos Respi 4 40KOLIBIN RC Neo 41MORAXEBIN Neo 42TRICHOBEN 43TRICHOBEN AV 44

3. Equine vaccinesBioEquin F 46BioEquin FH 47BioEquin FT 48BioEquin H 49CLOTEID 4 50FLUEQUIN 51FLUEQUIN T 52TRICHOEQUEN 53

4. Feline vaccinesBIOFEL M Plus 56BIOFEL PCH 57BIOFEL PCHR 58

5. Poultry vaccinesORNIBRON H120 Clone 60ORNIBRON H120+D274 61ORNIBUR Intermediate 62ORNIBUR Intermediate Plus 63ORNIMIX CLONE B1-Hitchner + H120 64ORNIPEST CLONE 65ORNIPRIM CLONE B1 66SALGEN 67ORNIDUCK 68ORNIVAC EDS 69ORNIVAC ND 70ORNIVAC ND+GO 71ORNIVAC ND+GO+IB+EDS 72ORNIVAC ND+IB2+EDS 73PMV-Salmovac 74

6. Rabbit vaccinesMYXOREN 76PASORIN-OL 77PESTORIN 78PESTORIN MORMYX 79TRICHOPELEN 80

7. Swine vaccinesBIOSUIS APP 2,9,11 82BIOSUIS M.hyo 83BIOSUIS PARVO L (6) 84BIOSUIS PRRS inact Eu+Am 85BIOSUIS Respi E 86ERYPESTEN 87ERYSEN 88ERYSIN SINGLE SHOT 89KOLIERYSIN Neo 90KOLISIN Neo 91PARVOERYSIN 92PARVOSIN-OL 93PESTISEN-C 94POLYPLEUROSIN APX PLUS IM 95RHINISIN DNT 96ROKOVAC NEO 97BIOSUIS PRRS live 98

8. HormonesLECIRELIN Bioveta 0.025 mg/ml 100

OESTROPHAN 0.25 mg/ml 101

OXYTOCIN BIO 5 IU/ml 102

REMOPHAN 75 μg/ml 103

SERGON 500 IU/ml 104

SERGON PG 400/200 IU 105

LIST OF PRODUCT BY THERAPEUTIC GROUPS

9. An�microbialsAMOXICILLIN Bioveta 150 mg/ml LA 108BIOVETA AMOXICILIN 100 mg/g 109BIOVETA COLISTIN 1 200 000 IU/g 110COTRIMAZIN BIOVETA 111GAMMAVIT BIO 112IVATYL TAR 180.000 IU/ml 113STREPTONAMID 114

10. An�parazi�csAn�parasi�c CANISSHAMPOO 116BIO KILL 2.5 mg/ml 117BIOMEC 10 mg/ml 118BLUE repellent 119CANIVERM forte 120CANIVERM mite 121CANIVERM oral paste 122EQUIMOXIN 18.92 mg/g 123EQUISTRONG 400 mg/g 124EQUIVERM Oral Paste 125ESB3 Bio 300 mg/g 126FIPRON 50 mg spot-on cats 127FIPRON 67 mg spot-on S 128FIPRON 134 mg spot-on M 129FIPRON 268 mg spot-on L 130FIPRON 402 mg spot-on XL 131FIPRON 2.5 mg/ml spray 132GREEN repellent 133SULFADIMIDIN BIOVETA 20 g 134TOP SPOT ON STRONGER 16.25 g 135TOP SPOT ON STRONGER 650 mg 136TOP SPOT ON DOG S 137TOP SPOT ON DOG M 138TOP SPOT ON DOG L 139

11. An�anaemicsFERRIBION 100 mg/ml 142GAFERVIT 143GAFERVIT mite 144

12. Anaesthe�csNALGOSED 10 mg/ml 146NARKAMON 100 mg/ml 147NARKAMON 50 mg/ml 148ROMETAR 20 mg/ml 149XYLASED 100 150XYLASED 500 151

13. IntramammaryGAMARET 154INTRAMAR LC 155LINEOMAM LC 156

LIST OF PRODUCT BY THERAPEUTIC GROUPS

14. Vitamins, mineralsADE - vit. 158ENERGY BOOSTER BIOVETA 159FRESH HORSE 160MULTIVIT – MINERAL 161PLASTIN 162VITA E SELEN 163VITAPLASTIN FORTE 164VITAPLASTIN tbl. 165

15. Joint nutri�onHYALCHONDRO DC Plus 168HYALCHONDRO EC Plus 169HYALURONAN BIOVETA 10 mg/ml 170

16. DermatologicsALAPTID 172BIODEXIN ear lo�on 173BIODEXIN shampoo 174BIOPIROX 10 mg/ml 175OTIBIOVIN ear drops 176OTIMIX ear drops 177OTIPUR ear drops 178OTOFINE 179PIX FAGI 180

17. An�seraCLOTEAN 182IMULYZIN 183POLYEQUAN 184POLYGLOB 185

19. Environmental disinfectants and insec�cidesBIO KILL insek�cidum 188IVASAN pets 189IVASAN farm 190IVASAN spray 191

20. OthersAQUA VIVA 194COFFEINUM BIOVETA 125 mg/ml 195JODOUTER 100 mg/ml 196LOTAGEN 360 mg/ml 197LOTAGEN injector 198PENBITAL 400 mg/ml 199PROFYMAST emulsio 200

Useful contact 201

Notes 202

DOGADE - vit. 158ALAPTID 172AMOXICILLIN Bioveta 150 mg/ml LA 108An�parasi�c CANISSHAMPOO 116BIO KILL 2.5 mg/ml 117Biocan B 12Biocan C 13Biocan DH + L 14Biocan DHPPi 15Biocan DHPPi + L 16Biocan DHPPi + LR 17Biocan DP 18Biocan L 19Biocan LR 20Biocan M 21Biocan M Plus 22Biocan NOVEL DHPPi 28Biocan NOVEL DHPPi/L4 29Biocan NOVEL DHPPi/L4R 30Biocan NOVEL Pi/L4 31Biocan NOVEL R 32Biocan P 23Biocan Puppy 24Biocan R 25Biocan T 26BIODEXIN ear lo�on 173BIODEXIN shampoo 174BIOPIROX 10 mg/ml 175Borrelym 3 27CANIVERM forte 120CANIVERM mite 121CANIVERM oral paste 122CLOTEAN 182CLOTEID 4 50COFFEINUM BIOVETA 125 mg/ml 195FERRIBION 100 mg/ml 142FIPRON 134 mg spot-on M 129FIPRON 2.5 mg/ml spray 132FIPRON 268 mg spot-on L 130FIPRON 402 mg spot-on XL 131FIPRON 67 mg spot-on S 128HYALCHONDRO DC Plus 168HYALURONAN BIOVETA 10 mg/ml 170LOTAGEN 360 mg/ml 197MULTIVIT – MINERAL 161NARKAMON 100 mg/ml 147NARKAMON 50 mg/ml 148OTIBIOVIN ear drops 176OTIMIX ear drops 177OTIPUR ear drops 178OTOFINE 179

OXYTOCIN BIO 5 IU/ml 102PENBITAL 400 mg/ml 199PIX FAGI 180PLASTIN 162POLYGLOB 185ROMETAR 20 mg/ml 149SERGON 500 IU/ml 104STREPTONAMID 114TOP SPOT ON DOG L 139TOP SPOT ON DOG M 138TOP SPOT ON DOG S 137TOP SPOT ON STRONGER 650 mg 136VITAPLASTIN FORTE 164VITAPLASTIN tbl. 165

CATALAPTID 172Biocan M 21Biocan R 25BIODEXIN shampoo 174BIOFEL M Plus 56BIOFEL PCH 57BIOFEL PCHR 58BIOPIROX 10 mg/ml 175CANIVERM forte 120CANIVERM mite 121CANIVERM oral paste 122CLOTEAN 182COFFEINUM BIOVETA 125 mg/ml 195FIPRON 2.5 mg/ml spray 132FIPRON 50 mg spot-on cats 127HYALURONAN BIOVETA 10 mg/ml 170LOTAGEN 360 mg/ml 197MULTIVIT – MINERAL 161NARKAMON 100 mg/ml 147NARKAMON 50 mg/ml 148OTIBIOVIN ear drops 176OTIPUR ear drops 178OTOFINE 179PENBITAL 400 mg/ml 199ROMETAR 20 mg/ml 149VITAPLASTIN tbl. 165

LIST OF PRODUCTS BY TARGET SPECIES

PESTORIN 78PESTORIN MORMYX 79PIX FAGI 180SERGON 500 IU/ml 104SULFADIMIDIN BIOVETA 20 g 134TRICHOPELEN 80VITAPLASTIN FORTE 164

EXOTIC BIRDSALAPTID 172BIO KILL 2.5 mg/ml 117BIOPIROX 10 mg/ml 175MULTIVIT – MINERAL 161PIX FAGI 180VITAPLASTIN FORTE 164

REPTILEALAPTID 172BIOPIROX 10 mg/ml 175MULTIVIT – MINERAL 161

CATTLEADE - vit. 158ALAPTID 172AMOXICILLIN Bioveta 150 mg/ml LA 108AQUA VIVA 194BioBos IBR marker in 34BioBos IBR marker live 35BioBos L 36BioBos L(6) 37BioBos Respi 2 intranasal 38BioBos Respi 3 39BioBos Respi 4 40Biocan R 25BIOMEC 10 mg/ml 118BIOVETA AMOXICILIN 100 mg/g 109BIOVETA COLISTIN 1 200 000 IU/g 110CLOTEAN 182CLOTEID 4 50COFFEINUM BIOVETA 125 mg/ml 195FERRIBION 100 mg/ml 142GAMARET 154GAMMAVIT BIO 112IMULYZIN 183INTRAMAR LC 155IVATYL TAR 180.000 IU/ml 113JODOUTER 100 mg/ml 196KOLIBIN RC Neo 41LECIRELIN Bioveta 0.025 mg/ml 100

HORSEADE - vit. 158ALAPTID 172BioEquin F 46BioEquin FH 47BioEquin FT 48BioEquin H 49BIOPIROX 10 mg/ml 175BLUE repellent 119CLOTEAN 182CLOTEID 4 50COFFEINUM BIOVETA 125 mg/ml 195COTRIMAZIN BIOVETA 111ENERGY BOOSTER BIOVETA 159EQUIMOXIN 18.92 mg/g 123EQUISTRONG 400 mg/g 124EQUIVERM Oral Paste 125FERRIBION 100 mg/ml 142FLUEQUIN 51FLUEQUIN T 52FRESH HORSE 160GREEN repellent 133HYALCHONDRO EC Plus 169HYALURONAN BIOVETA 10 mg/ml 170MULTIVIT – MINERAL 161NARKAMON 100 mg/ml 147NARKAMON 50 mg/ml 148OESTROPHAN 0.25 mg/ml 101OXYTOCIN BIO 5 IU/ml 102PENBITAL 400 mg/ml 199PIX FAGI 180POLYEQUAN 184ROMETAR 20 mg/ml 149STREPTONAMID 114TOP SPOT ON STRONGER 16.25 g 135TRICHOEQUEN 53VITAPLASTIN FORTE 164XYLASED 100 150XYLASED 500 151

RABBITADE - vit. 158ALAPTID 172BIOPIROX 10 mg/ml 175CLOTEAN 182ESB3 Bio 300 mg/g 126LECIRELIN Bioveta 0.025 mg/ml 100MULTIVIT – MINERAL 161MYXOREN 76PASORIN-OL 77PENBITAL 400 mg/ml 199


LINEOMAM LC 156LOTAGEN 360 mg/ml 197

PIX FAGI 180PROFYMAST emulsio 200SERGON 500 IU/ml 104SULFADIMIDIN BIOVETA 20 g 134VITA E SELEN 163

POULTRYALAPTID 172BIOVETA AMOXICILIN 100 mg/g 109BIOVETA COLISTIN 1 200 000 IU/g 110ESB3 Bio 300 mg/g 126MULTIVIT – MINERAL 161ORNIBRON H120 Clone 60ORNIBRON H120+D274 61ORNIBUR Intermediate 62ORNIBUR Intermediate Plus 63ORNIDUCK 68ORNIMIX CLONE B1-Hitchner + H120 64ORNIPEST CLONE 65ORNIPRIM CLONE B1 66ORNIVAC EDS 69ORNIVAC ND 70ORNIVAC ND+GO 71ORNIVAC ND+GO+IB+EDS 72ORNIVAC ND+IB2+EDS 73PIX FAGI 180PLASTIN 162PMV-Salmovac 74SALGEN 67SULFADIMIDIN BIOVETA 20 g 134VITAPLASTIN FORTE 164

FUR-BEARING ANIMALBiocan R 25PENBITAL 400 mg/ml 199PIX FAGI 180TRICHOPELEN 80VITAPLASTIN FORTE 164VITAPLASTIN tbl. 165

ENVIROMENTBIO KILL 2.5 mg/ml 117BIO KILL insek�cidum 188IVASAN pets 189IVASAN farm 190IVASAN spray 191


dog

cat

horse

rabbit

exo�c birds

rep�le

ca�le

swine

goat

sheep

poultry

fur-bearing animal

environment


ADE - vit. 158ALAPTID 172AMOXICILLIN Bioveta 150 mg/ml LA 108An�parasi�c CANISSHAMPOO 116AQUA VIVA 194

BIO KILL 2.5 mg/ml 117BIO KILL insek�cidum 188BioBos IBR marker in 34BioBos IBR marker live 35BioBos L 36BioBos L(6) 37BioBos Respi 2 intranasal 38BioBos Respi 3 39BioBos Respi 4 40Biocan B 12Biocan C 13Biocan DH + L 14Biocan DHPPi 15Biocan DHPPi + L 16Biocan DHPPi + LR 17Biocan DP 18Biocan L 19Biocan LR 20Biocan M 21Biocan M Plus 22Biocan NOVEL DHPPi 28Biocan NOVEL DHPPi/L4 29Biocan NOVEL DHPPi/L4R 30Biocan NOVEL Pi/L4 31Biocan NOVEL R 32Biocan P 23Biocan Puppy 24Biocan R 25Biocan T 26BIODEXIN ear lo�on 173BIODEXIN shampoo 174BioEquin F 46BioEquin FH 47BioEquin FT 48BioEquin H 49BIOFEL M Plus 56BIOFEL PCH 57BIOFEL PCHR 58BIOMEC 10 mg/ml 118BIOPIROX 10 mg/ml 175BIOSUIS APP 2,9,11 82BIOSUIS M.hyo 83BIOSUIS PARVO L (6) 84BIOSUIS PRRS inact Eu+Am 85BIOSUIS PRRS live 98BIOSUIS Respi E 86BIOVETA AMOXICILIN 100 mg/g 109BIOVETA COLISTIN 1 200 000 IU/g 110

BLUE repellent 119Borrelym 3 27

CANIVERM forte 120CANIVERM mite 121CANIVERM oral paste 122CLOTEAN 182CLOTEID 4 50COFFEINUM BIOVETA 125 mg/ml 195COTRIMAZIN BIOVETA 111

ENERGY BOOSTER BIOVETA 159EQUIMOXIN 18.92 mg/g 123EQUISTRONG 400 mg/g 124EQUIVERM Oral Paste 125ERYPESTEN 87ERYSEN 88ERYSIN SINGLE SHOT 89ESB3 Bio 300 mg/g 126

FERRIBION 100 mg/ml 142FIPRON 134 mg spot-on M 129FIPRON 2.5 mg/ml spray 132FIPRON 268 mg spot-on L 130FIPRON 402 mg spot-on XL 131FIPRON 50 mg spot-on cats 127FIPRON 67 mg spot-on S 128FLUEQUIN 51FLUEQUIN T 52FRESH HORSE 160

GAFERVIT 143GAFERVIT mite 144GAMARET 154GAMMAVIT BIO 112GREEN repellent 133

HYALCHONDRO DC Plus 168HYALCHONDRO EC Plus 169HYALURONAN BIOVETA 10 mg/ml 170

IMULYZIN 183INTRAMAR LC 155IVASAN farm 190IVASAN pets 189IVASAN spray 191IVATYL TAR 180.000 IU/ml 113

JODOUTER 100 mg/ml 196

KOLIBIN RC Neo 41KOLIERYSIN Neo 90KOLISIN Neo 91

ALPHABETICAL LIST OF PRODUCTS

LECIRELIN Bioveta 0.025 mg/ml 100LINEOMAM LC 156LOTAGEN 360 mg/ml 197LOTAGEN injector 198

MORAXEBIN Neo 42MULTIVIT – MINERAL 161MYXOREN 76

NALGOSED 10 mg/ml 146NARKAMON 100 mg/ml 147NARKAMON 50 mg/ml 148

OESTROPHAN 0.25 mg/ml 101ORNIBRON H120 Clone 60ORNIBRON H120+D274 61ORNIBUR Intermediate 62ORNIBUR Intermediate Plus 63ORNIDUCK 68ORNIMIX CLONE B1-Hitchner + H120 64ORNIPEST CLONE 65ORNIPRIM CLONE B1 66ORNIVAC EDS 69ORNIVAC ND 70ORNIVAC ND+GO 71ORNIVAC ND+GO+IB+EDS 72ORNIVAC ND+IB2+EDS 73OTIBIOVIN ear drops 176OTIMIX ear drops 177OTIPUR ear drops 178OTOFINE 179OXYTOCIN BIO 5 IU/ml 102

PARVOERYSIN 92PARVOSIN-OL 93PASORIN-OL 77PENBITAL 400 mg/ml 199PESTISEN-C 94PESTORIN 78PESTORIN MORMYX 79PIX FAGI 180PLASTIN 162PMV-Salmovac 74POLYEQUAN 184POLYGLOB 185POLYPLEUROSIN APX PLUS IM 95PROFYMAST emulsio 200

REMOPHAN 75 μg/ml 103RHINISIN DNT 96ROKOVAC NEO 97ROMETAR 20 mg/ml 149

SALGEN 67SERGON 500 IU/ml 104SERGON PG 400/200 IU 105STREPTONAMID 114SULFADIMIDIN BIOVETA 20 g 134

TOP SPOT ON DOG L 139TOP SPOT ON DOG M 138TOP SPOT ON DOG S 137TOP SPOT ON STRONGER 16.25 g 135TOP SPOT ON STRONGER 650 mg 136TRICHOBEN 43TRICHOBEN AV 44TRICHOEQUEN 53TRICHOPELEN 80

VITA E SELEN 163VITAPLASTIN FORTE 164VITAPLASTIN tbl. 165

XYLASED 100 150XYLASED 500 151

ALPHABETICAL LIST OF PRODUCTS

dog

cat

horse

rabbit

exo�c birds

rep�le

ca�le

swine

goat

sheep

poultry

fur-bearing animal

environment

Biocan B Biocan C

Biocan DH + L Biocan DHPPi

Biocan DHPPi + L Biocan DHPPi + LR

Biocan DP Biocan L

Biocan LR Biocan M

Biocan M Plus Biocan P

Biocan Puppy Biocan R Biocan T

Borrelym 3Biocan NOVEL DHPPi

Biocan NOVEL DHPPi/L4 Biocan NOVEL DHPPi/L4R

Biocan NOVEL Pi/L4Biocan NOVEL R

CANINE VACCINES

1

Great protec�on against two the most common European serogroups of Borrelia spp.

COMPOSITIONComposi�on 1 ml:Ac�ve substances:Borrelia burgdorferi inac�vata:

Borrelia garinii RP ł 1*

Borrelia afzelii RP ł 1** rela�ve potency (RP) in comparison with reference serum gained from the animals vaccinated with batch which sa�sfied in challenge test on target animal

TARGET SPECIESDogs.

INDICATIONFor the ac�ve immuniza�on of dogs against Lyme disease at the age of 12 weeks and above.It can be applied simultaneously with other vaccines of Biocan type, but always each vaccine shall be applied to the individual spot (preferably on the opposite body side).

STORAGEStore in a dark and dry place at the temperature between 2 °C – 8 °C. The vaccine shall not be allowed to freeze.

PACKAGE2 × 1 ml, 10 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml

12

Biocan B suspension for injec�on

1 Canine vaccines

DOSAGE1 ml irrespec�ve of age, weight and race of the individual, but not early than at the age of 12 weeks. Apply the vaccine: - subcutaneously, preferably at the region behind the blade-bone - intramuscularly, preferably to the musculature of the pelvis extremity.In case of the primary vaccina�ons, the re-vaccina�on shall be performed at the interval of 14–21 days. The vaccina�on scheme should be specified by the veterinarian in dependence on the infec�on situa�on.

SHELF LIFE24 months

Vaccine against Lyme disease, inac�vated

Vaccine providing protec�on against the next viral pathogen of gastrointes�nal tract

COMPOSITIONComposi�on – 1 ml:Ac�ve substance:Coronavirus gastroenteri�dis infec�osae canis, prior to

6,5inac�va�on min. 10 TCID50

TARGET SPECIESDogs.

INDICATIONFor ac�ve immunisa�on from 5th week of age against canine coronavirus.

SHELF LIFE24 months. Use the vaccine immediately a�er opening.

STORAGEStore in a dark and dry place under a temperature

o oof 2 C – 8 C. The vaccine must not get frozen!

PACKAGE10 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml

13

Biocan C suspension for injec�on

1 Canine vaccines

DOSAGE1 ml regardless of age, weight and breed of the individual.The vaccine is administered subcutaneously at the age of 5 weeks and above; revaccina�on is performed in 14 to 21 days a�er primovaccina�on. To maintain a permanent immunity, it is recommended to revaccinate in six-month intervals.

Inac�vated canine coronavirus vaccine

Unique an�genic combina�on for special epidemiological situa�on

COMPOSITIONComponent DH (freeze-dried):Virus febris contagiosae canis

3.0 4.5 50min. 10 TCID , max. 10 TCID50Virus laryngotrachei�dis contagiosae canis

3.5 4.5min. 10 TCID , max. 10 TCID50 50Nutrimentum pro lyophilisa�onead 1 mlComponent L (solu�on):Leptospira icterohaemorrhagiae inact. min. �tre 32 defined MAT*)Leptospira canicola inact.min. �tre 32 defined MAT*)Leptospira grippotyphosa inact.min. �tre 32 defined MAT*)*) geometrical mean of �tres of specific an�bodies defined by microagglu�na�on test

TARGET SPECIESDogs.

SHELF-LIFE24 months. When diluted, the vaccine shall be used immediately.

STORAGEStore in a dry and dark place at the temperature of 2 °C – 8 °C. Do not freeze!

PACKAGE5 × 1 ml of the vaccine Biocan L + 5 × 1 ml of the lyophilised vaccine Biocan DH 10 × 1 ml of the vaccine Biocan L + 10 × 1 ml of the lyophilised vaccine Biocan DH50 × 1 ml of the vaccine Biocan L + 50 × 1 ml of the lyophilised vaccine Biocan DHl

14

Biocan DH + L lyophilisate for the prepara�on of injec�on suspension with diluent

1 Canine vaccines

INDICATIONFor the ac�ve immuniza�on of dogs against distemper, infec�ous hepa��s, infec�ous laryngotrachei�s and the most frequently occurred leptospira serovars (Leptospira icterohaemorrhagiae, Leptospira canicola, Leptospira grippotyphosa) in dogs at the age of 8 weeks and above.Use during pregnancy and lacta�onVaccina�on should be avoided during the last two weeks before delivery for the general purposes (handling with pregnant animal, etc.).

DOSAGEDose – 1 ml irrespec�ve of age, weight and breed.

Vaccine against canine distemper (CDV), inf. hepa��s (CAV-1), inf. laryngotrachei�s (CAV-2) vivid and leptospirosis (L. icterohaemorrhagiae inact., L. canicola inact., L. grippotyphosa inact.) in dogs inac�vated.

Live vaccine for the first shot in puppies at the age six weeks

COMPOSITIONComposi�on – 1 ml:Freeze-dried component:Virus febris contagiosae canis

3,0 4,5min. 10 TCID , max.10 TCID50 50Virus laryngotrachei�dis

3,5contagiosae canis min. 10 4,5 50TCID , max.10 TCID50

Parvovirus enteri�dis canis4,5 5,5min. 10 TCID , max.10 TCID50 50

Virus parainfluensis canis3,0 4,2min. 10 TCID , max.10 TCID50 50

TARGET SPECIESDogs.

INDICATIONFor the ac�ve immuniza�on of dogs against distemper, infec�ous hepa��s, infec�ous laryngotrachei�s, parvovirosis and parainfluenza.

STORAGEStore in a dry and dark place at the temperature of 2 °C – 8 °C.

PACKAGE5 × 1 ml of vaccine Biocan DHPPi + 5 × 1 ml of diluent 10 × 1 ml of vaccine Biocan DHPPi + 10 × 1 ml of diluent50 × 1 ml of vaccine Biocan DHPPi + 50 × 1 ml of diluent

15

Biocan DHPPilyophilisate for prepara�on of solu�on for injec�on

1 Canine vaccines

INTERACTIONThe vaccine Biocan DHPPi can be used separately or simultaneously with other vaccines Biocan according to recommended vaccina�on scheme or in group with fluid vaccines Biocan (LR, L, C, R).

DOSAGE The dose is 1 ml regardless of age, weight and breed of the individual, vaccina�on may be first performed during the sixth week of age.Method of administra�on – subcutaneously, preferably in zone behind the shoulder-blade.

SHELF LIFE24 months. When diluted, the vaccine shall be used immediately.

Live vaccine against canine distemper (CDV), inf. laryngotrachei�s (CAV-2), inf. hepa��s (CAV-1), parvovirosis (CPV-2), parainfluenza (CPIV-2) in dogs.

Combina�on viral an�gens and three serogroups of Leptospira spp. for purpose of revaccina�on at the age eight weeks

COMPOSITIONFreeze-dried componentVirus febris contagiosae canis

3.0 4.5 min. 10 TCID , max. 10 TCID50 50Virus laryngotrachei�dis contagiosae canis

3.5 4.5min. 10 TCID , max. 10 TCID50 50Parvovirus enteri�dis canis

4.5 5.5min. 10 TCID , max. 10 TCID50 50Virus parainfluensis canis

3.0 4.2min. 10 TCID , max. 10 TCID 50 50Liquid componentLeptospira icterohaemorrhagiae inact. min. �tre 32 defined MAT*)Leptospira canicola inac. min. �tre 32 defined MAT*)Leptospira grippotyphosa inact.min. �tre 32 defined MAT*)*) geometrical mean of �tres of specific an�bodies defined by microagglu�na�on test

TARGET SPECIESDogs

INDICATION For the ac�ve immuniza�on of dogs against distemper, infec�ous

immunity of the animals vaccinated.

SHELF LIFE24 months.When diluted, the vaccine shall be used immediately.

STORAGEStore in a dry and dark place at the temperature of 2 °C – 8 °C.Do not freeze!

PACKAGE5 × 1 ml of freeze-dried DHPPi component + 5 × 1 ml of L component10 × 1 ml of freeze-dried DHPPi component + 10 × 1 ml of L component50 × 1 ml of freeze-dried DHPPi component + 50 × 1 ml of L component

16

Biocan DHPPi + L lyophilisate for the prepara�on of injec�on suspension with diluent

1 Canine vaccines

hepa��s, infec�ous laryngotrachei�s, parvovirosis, parainfluenza and the most frequently occurred leptospira serovars (Leptospira icterohaemorrhagiae, Leptospira canicola, Leptospira grippotyphosa) in dogs at the age of 8 weeks and above.

DOSAGEDose - 1 ml irrespec�ve of age, weight and breed.Vaccine is administered subcutaneously, preferably in zone behind the shoulder-blade at the age of 8 weeks and above, the re-vaccina�on shall be done within 14–21 day.Immunity is star�ng a�er 14 days a�er first vaccina�on and firm immunity is developed a�er further 14 days a�er re-vaccina�on. The revaccina�on shall be performed within 14–21 days. The revaccina�on should be repeated every year in order to keep permanent

Vaccine against canine distemper (CDV), inf. hepa��s (CAV-1), inf. laryngotrachei�s (CAV-2), parvovirosis (CPV-2), parainfluenza (CPIV-2) vivid and leptospirosis (L. icterohaemorrhagiae inact., L. canicola inact., L. grippotyphosa inact.) in dogs inac�vated

For effec�ve final vaccina�on of puppies at the age of 12 weeks

COMPOSITIONComponent DHPPi - lyophilizateAc�ve substances:Virus febris contagiosae canis

3,0 4,5min. 10 , max. 10 TCID50Virus laryngotrachei�dis contagiosae canis

3,5 4,5min. 10 , max. 10 TCID50Parvovirus enteri�dis canis

4,5 5,5min. 10 , max. 10 TCID50Virus parainfluensis canis

3,0 4,2min. 10 , max. 10 TCID50Component LR - diluentAc�ve substances:Virus rabiei inac�vatedmin. 2 IULeptospira icterohaemorrhagiae inact.min. �tre 32 defined by MAT*)Leptospira canicola inact.min. �tre 32 defined by MAT*)Leptospira grippotyphosa inact.min. �tre 32 defined by MAT*)*) geometrical mean of �tres of specific an�bodies defined by microagglu�na�on test

TARGET SPECIESDogs.

Immunity is star�ng a�er 14 days a�er first vaccina�on and firm immunity is developed a�er further 14 days a�er re-vaccina�on. The revaccina�on shall be performed within 14–21 days. The revaccina�on should be repeated every year in order to keep permanent immunity of the animals vaccinated.

SHELF LIFE24 months.

STORAGEStore in a dry and dark place at the temperature of 2 °C – 8 °C.Do not freeze!

PACKAGE 5 × 1 ml of the vaccine Biocan LR + 5 × 1 ml of the lyophilised vaccine Biocan DHPPi 10 × 1 ml of the vaccine Biocan LR + 10 × 1 ml of the lyophilised vaccine Biocan DHPPi 50 × 1 ml of the vaccine Biocan LR + 50 × 1 ml of the lyophilised vaccine Biocan DHPPi.

17

Biocan DHPPi + LR lyophilisate for the prepara�on of injec�on suspension with diluent

1 Canine vaccines

INDICATIONFor the ac�ve immuniza�on of dogs against distemper, infec�ous hepa��s, infec�ous laryngotrachei�s, parvovirosis, parainfluenza, rabies and the most frequently occurred leptospira serovars (Leptospira icterohaemorrhagiae, Leptospira canicola, Leptospira grippotyphosa) in dogs at the age of 12 weeks and above.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONThe vaccine Biocan DHPPi + LR can be used separately or simultaneously with vaccines Biocan C, Biocan M Plus, Biocan B.

DOSAGE1 ml irrespec�ve of weight of breed, at the age of 12 weeks and above.Method of administra�on – subcutaneously.

Vaccine against canine distemper (CDV), inf. hepa��s (CAV-1), inf. laryngotrachei�s (CAV-2), parvovirosis (CPV-2), parainfluenza (CPIV-2) vivid and leptospirosis and rabies in dogs inac�vated

Vaccine contains live, highly immunogenic strain of parvovirus inducing fast onset of immunity

COMPOSITIONLyophilisate:Virus febris contagiosae canis:

3.0 4.810 – 10 TCID50Parvovirus enteri�dis canis:

4.5 6.010 – 10 TCID50Excipients: lyophilisa�on medium ad 1 ml

TARGET SPECIESDogs.

INDICATIONSFor ac�ve immuniza�on of dogs against canine distemper and canine parvovirus from 6th week of age.The onset of immunity is 14 to 28 days a�er the second vaccina�on. The dura�on of immunity to both the an�gens is at least one year.

PACKAGE5 × 1 ml of lyophilised vaccine Biocan DP + 5 × 1 ml of diluent 10 × 1 ml of lyophilised vaccine Biocan DP + 10 × 1 ml of diluent 50 × 1 ml of lyophilised vaccine Biocan DP + 50 × 1 ml of diluent

18

Biocan DP lyophilisate for suspension for injec�on with diluent

1 Canine vaccines

DOSAGEDose: 1 ml regardless of age, weight and breed of the individual, but not earlier than at the 6th week of age. Method of administra�on – subcutaneous, preferably in the region behind the shoulder blade.

SHELF LIFE24 months, the vaccine should be used immediately a�er dilu�on.

STORAGEStore in a dry and dark place at 2 °C – 8 °C.

Vaccine against canine distemper (CDV) and canine parvovirus (CPV-2), live

The content of three recommended serovars of Leptospira species

COMPOSITIONAc�ve substances:Leptospira icterohaemorrhagiae inact.min. �tre 32 defined by MAT*)Leptospira canicola inact.min. �tre 32 defined by MAT*)Leptospira grippotyphosa inact.min. �tre 32 defined by MAT*)*) geometrical mean of �tres of specific an�bodies defined by microagglu�na�on test

TARGET SPECIESDogs

INDICATIONFor ac�ve immunisa�on of dogs from the age of 8 weeks against leptospiral serovars contained in vaccine.

STORAGEStore in a dark and dry place under a temperature of 2 °C – 8 °C. The vaccine must not get frozen!

PACKAGE10 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml.

19

Biocan L suspension for injec�on

1 Canine vaccines

DOSAGE1 ml regardless of age, weight and breed of the individual. The vaccine is administered subcutaneously at the age of 8 weeks or more. Revaccina�on is performed in 14 to 28 days a�er primovaccina�on so that revaccina�on was performed at least at the age of 12 weeks of the puppies.Annual revaccina�on is recommended in order to maintain permanent immunity.


Inac�vated vaccine against leptospirosis in dogs

A combina�on three Leptospira serovars and rabies virus in one vial

COMPOSITIONAc�ve substances:Virus rabiei inac�vated min. 2 IULeptospira icterohaemorrhagiae inact. min. �tre 32 defined by MAT*)Leptospira canicola inact.min. �tre 32 defined by MAT*)Leptospira grippotyphosa inact.min. �tre 32 defined by MAT*)*) geometric mean of �tres of specific an�bodies defined by micro-agglu�na�on test

TARGET SPECIESDogs.

INDICATIONFor ac�ve immunisa�on of dogs against rabies and leptospira serovars contained in vaccine.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONBiocan LR vaccine may be used separately, simultaneously or in combina�on with other Biocan vaccines:

Primary vaccina�on at the age of 12 weeks.Vaccina�on with Biocan LR vaccine with subsequent revaccina�on with Biocan L vaccine within an interval of 14–28 days. To maintain permanent immunity against leptospira and rabies, it is recommended to revaccinate yearly with Biocan LR vaccine.


STORAGEStore in a dark and dry place at 2 °C – 8 °C. The vaccine must not get frozen!

PACKAGE10 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml.

20

Biocan LR suspension for injec�on

1 Canine vaccines

A/ Biocan LR vaccine may be used as a diluent for other lyophilised Biocan vaccines (for example DHPPi, DHP, DP, P). B/ Biocan LR vaccine may be administered simultaneously or with liquid vaccines Biocan C, Biocan B and Biocan M (possibly with lyophilised vaccine Biocan DHPPi).

DOSAGE1 ml subcutaneously regardless of age, weight and breed of the individual.Vaccina�on scheme: Primary vaccina�on at the age of 8 weeks. If necessary, it is possible to vaccinate puppies at the age from 8 weeks with Biocan L or Biocan LR vaccine (in case of rabies in the area). Revaccina�on in this case is performed at the age of 12 weeks using Biocan LR vaccine. To maintain permanent immunity against leptospira and rabies, it is recommended to revaccinate yearly with Biocan LR vaccine.

Inac�vated vaccine against leptospirosis and rabies in dogs

Unique vaccine for prophylaxis and treatment of the dermatophytosis in dogs and cats

COMPOSITIONAc�ve substance:Microsporum canis inact. min. 500 000 vegeta�ve forms

TARGET SPECIESDog, cat.

INDICATIONFrom the 12th week of age for the prophylaxis and therapy of dermal mycosis in dogs and cats caused by the dermatophyte Microsporum canis.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONAlways apply Biocan M separately (never use it as a diluent for lyophilized vaccines or mix with liquid Biocan vaccines).Any other Biocan vaccine (Puppy, P, DP, DH, DHP, DHPPi, L, R, LR, C) can be administered simultaneously with Biocan M into a different site (preferably on the other side).

SHELF LIFE24 months

STORAGEKeep in a dry and dark place at 2 °C – 8 °C. Do not freeze.

PACKAGE2 × 1 ml, 10 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml.

21

Biocan M inj. ad us. vet.

1 Canine vaccines

DOSAGE1 ml regardless of age, weight or bread of the animal. Dogs: strictly intramuscularly into the hind limb muscle.Cats: subcutaneously into the area behind the blade bone or intramuscularly into the hind limb muscle.Preferably vaccinate into the le� and revaccinate into the right half of the body.

Vaccine against Microsporum canis in dogs and cats

Inac�vated non-adjuvant vaccine against Microsporum canis infec�onin dogs

COMPOSITIONAc�ve substance:Microsporum canis inact.min. 1 million of vegeta�ve forms

TARGET SPECIESDogs.

INDICATIONFor the preven�on and therapy of dermal mycoses in dogs induced by the dermatophyte Microsporum canis. Animals should be vaccinated at the age of 2 months and above. The immunity develops within 1 month a�er revaccina�on and persists for at least 1 year.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONOther immunoprophylac�c interven�ons should not be carried out during one week before the first vaccina�on up to 14 days a�er the second (or, if relevant, the third) vaccina�on (except of the cases when the vaccine BIOCAN series is applied).

SHELF LIFE18 months

STORAGEStore in a refrigerator

o o(2 C – 8 C). Do not freeze. Protect from light

PACKAGE2 × 1 ml,10 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml.

22

Biocan M Plus injec�on suspension for dogs

1 Canine vaccines

DOSAGEOne ml of the vaccine can be applied to animals aged two months and above, regardless of the age, weight and race of the individual Applica�on: deep intramuscularly into the musculature of the pelvis extremity.The vaccina�on should be carried out into the le� body side and the revaccina�on into the right body side.Preven�ve and therapeu�c use: animals shall be vaccinated twice at the interval of 10–21 days between the first and the second vaccina�on. The third vaccina�on dose can be applied, if necessary for therapeu�c purposes, 10–21 days a�er the revaccina�on.

Inac�vated vaccine against Microsporum canis in dogs

Monovalent protec�on against canine parvovirosis in special situa�on

COMPOSITIONFreeze – dried component:Ac�ve substance:Parvovirus enteri�dis canis

5.0 6.2min. 10 TCID , max.10 TCID50 50Auxiliary substances:Nutrimentum pro lyophilisa�one ad 1 mlDiluentAqua pro injec�one1 ml

TARGET SPECIESDogs.

INDICATION For the ac�ve immuniza�on of dogs against parvovirosis.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONThe vaccine Biocan P can be used separately or simultaneously with other vaccines Biocan according to recommended vaccina�on scheme or in group with fluid vaccines Biocan (LR, L, C, R).

PACKAGE5 × 1 ml of vaccine Biocan P + 5 × 1 ml of diluent 10 × 1 ml of vaccine Biocan P + 10 × 1 ml of diluent50 × 1 ml of vaccine Biocan P + 50 × 1 ml of diluent

23

Biocan P inj. sicc. ad us. vet.

1 Canine vaccines

DOSAGEThe dose is 1 ml regardless of age, weight and breed of the individual, vaccina�on may be first performed during the sixth week of age.Method of administra�on – subcutaneously, preferably in zone behind the shoulder-blade.SHELF LIFE24 months, when diluted, the vaccine shall be used immediately.

STORAGEStore in a dry and dark place at the temperature of 2 °C – 8 °C.

Live vaccine against parvovirosis (CPV-2) in dogs

Safe vaccine for the vaccina�on of the youngiest puppies at 5th weeksof age

COMPOSITIONLyophilized component (D)Virus febris contagiosae canis

4,2 5,0min. 10 TCID – max 10 TCID50 50Liquid component (P)Parvovirus enteri�dis canis inact. min. 1024 HAU – max 4096 HAU

TARGET SPECIESDogs.INDICATIONFor an ac�ve immunisa�on of dogs against canine distemper and parvovirosis from 5th week of age.

DOSAGE Dose - 1 ml of injec�on solu�on, which is prepared by dilu�ng the lyophilised component with liquid component of the vaccine, regardless of age, weight and breed of the animal, but at the earliest in the fi�h week of age. Method of administra�on – subcutaneous, best to the region behind scapula. Individuals vaccinated for the first �me need to be revaccinated

50 × 1 ml of lyophilised component of the vaccine Biocan Puppy (Component D) 50 × 1 ml of liquid component of the vaccine Biocan Puppy (Component P)

24

Biocan Puppy lyophilisate for the prepara�on of injec�on suspension with diluent

1 Canine vaccines

within an interval of 14–21 days. Yearly revaccina�on is recommended in order to maintain a permanent immunity.

SHELF LIFE24 month, use the vaccine immediately a�er recons�tu�on.

STORAGEStore in a dry and dark place

o oat 2 C – 8 C. The vaccine must not get frozen!

PACKAGE5 × 1 ml of lyophilised component of the vaccine Biocan Puppy (Component D) 5 × 1 ml of liquid component of the vaccine Biocan Puppy (Component P)10 × 1 ml of lyophilised component of the vaccine Biocan Puppy (Component D) 10 × 1 ml of liquid component of the vaccine Biocan Puppy (Component P)

Live vaccine against canine distemper and inac�vated vaccine against canine parvovirosis

Monovalent vaccine with immunogenic rabies virus SAD Vnukovo – 32

COMPOSITIONAc�ve ingredientVirus rabiei inac�vatum, strain SAD Vnukovo – 32min. 2 IU

TARGET SPECIESDogs, cats, fur animals, ca�le, horses, sheep, goats, pigs.

INDICATION For ac�ve immunisa�on of target animal species against rabies.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONBiocan R vaccine may be used separately, simultaneously or in combina�on with other Biocan vaccines:A/ Biocan R vaccine may be used as a diluent for other lyophilised Biocan vaccines (for example DHPPi, DP, P). B/ Biocan R vaccine may be administered simultaneously or with liquid vaccines Biocan C, Biocan B, Biocan M and Biocan L.

recommended to revaccinate in accordance with veterinary regula�ons of each country.

SHELF LIFE24 months, to be used within 8 hours a�er the first opening.

STORAGEStore in a dry and dark place at a temperature 2 °C – 8 °C. Do not freeze!

PACKAGE10 × 1 ml, 20 × 1 ml, 50 × 1, 100 × 1 ml, 1 × 5 ml, 5 × 5 ml, 10 × 5 ml, 1 × 10 ml, 5 × 10 ml, 10 × 10 ml, 1 × 20 ml, 5 × 20 ml, 10 × 20 ml

25

Biocan R suspension for injec�on

1 Canine vaccines

DOSAGEDosage – 1 ml regardless of age, weight and breed of the individual; but at the earliest in the 12th week of age.Method of administra�on:- subcutaneous, best in the region behind the shoulder blade.- intramuscular, best to the muscle of the rear limb.Animals are vaccinated from the age of 3 months. The onset of protec�ve immunity is within 14 days a�er immunisa�on. Animals vaccinated earlier than at the age of 3 months must be revaccinated a�er reaching this age (minimal 14 day interval between vaccina�ons must be observed). Animals vaccinated for the first �me, at the age of 3–12 months, must be revaccinated in 1 year a�er the first applica�on of the vaccine. Revaccina�on performed one year a�er the first vaccine protects animals against rabies for at least 2 years. In order to maintain immunity, it is

Inac�vated vaccine against rabies

Toxoid vaccine containing toxoid of Clostridium tetani for ac�ve protec�on against neurological symptoms of disease

COMPOSITIONComposi�on – 1 ml:Ac�ve substanceAnatoxinum tetanicum purificatum min. 7.5 IU

TARGET SPECIESDogs.

INDICATIONAc�ve immuniza�on of dogs against tetanus.

DOSAGE AND METHOD OF ADMINISTRATION2 × 1 ml at the interval of 3 weeks (animals at the age of 3 months and above).

PACKAGE2 × 1 ml, 5 × 1 ml, 10 × 1 ml, 20 × 1 ml, 1 × 2 ml.

26

Biocan T injec�on suspension for dogs

1 Canine vaccines

METHOD OF ADMINISTRATION Intramuscularly.

SHELF LIFE36 months, usable life a�er the first opening is max. 10 hours.

STORAGE Store in a dry and dark place at a temperature between 2 °C – 8 °C. Shake well the vial content before use.

Vaccine against tetanus in dogs

Novel vaccine protected against all the most pathogenic serogroups of Borrelia spp.

COMPOSITIONComposi�on of one dose (1 ml): Ac�ve substances:Inac�vated Borrelia burgdorferi sensu lato:

Borrelia garinii RP ł 1*

Borrelia afzelii RP ł 1*Borrelia burgdorferi sensu stricto

RP ł 1**RP = Rela�ve potency (ELISA test) compared with the reference serum obtained a�er vaccina�on of mice with a vaccine batch that has successfully passed the challenge test in the target species.

Suspension for injec�on.Pinkish up to white fluid containing white sediment that disperses easily when the content is shaken.

TARGET SPECIESDogs.

INDICATION For ac�ve immuniza�on of dogs from 12 weeks of age, to induce an an�-OspA response against Borrelia spp. (B. burgdorferi sensu stricto, B. garinii and B. afzelii).

STORAGEProtect from light. Store and transport at 2 °C – 8 °C.STORAGE 10 × 1 ml, 2 × 1 ml, 20 × 1 ml, 50 × 1 ml, 100 × 1 ml.

27

Borrelym 3 injec�on suspension for dogs

1 Canine vaccines

Onset of immunity: 1 month a�er primary vaccina�on.Dura�on of immunity: one year a�er primary vaccina�on.

DOSAGE 1 ml from 12 weeks of age.Subcutaneously. Shake the vial well before use.Primary vaccina�on:Administer two doses separated by an interval of 3 weeks.Revaccina�on:Annual revaccina�on with a single dose is recommended to maintain immunity although this schedule has not been inves�gated.Vaccina�on should be carried out prior to periods of increased �ck ac�vity, allowing sufficient �me for the immune response to vaccina�on to develop fully prior to expected �ck exposure.

SHELF LIFE24 months.

Vaccine against Lyme disease

Live vaccine containing new highly immunogenic parvo strain CPV 2b

COMPOSITIONFreeze-dried frac�on (live a�enuated):Canine Distemper virus, strain CDV Bio 11/A

3.1min. 10 TCID max. 10 TCID 50 5.1 50Canine Adenovirus Type 2, strain CAV-2-Bio 13

3.6min. 10 TCID max. 10 TCID 50 5.3 50Canine Parvovirus Type 2b, strain CPV-2b-Bio 12/B

4.3min. 10 TCID max. 10 TCID 50 6.6 50Canine Parainfluenza virus, strain CPiV-Bio 15

3.1 5.1min. 10 TCID max. 10 TCID 50 50

INDICATIONAc�ve immuniza�on of dogs from 6 weeks of age.to prevent mortality and clinical signs caused by canine distemper virusto prevent mortality and clinical signs caused by canine adenovirus type 1to prevent clinical signs and reduce viral excre�on caused by canine adenovirus type 2to prevent clinical signs, leukopenia and viral excre�on caused by canine to prevent clinical signs (nasal and ocular discharge) and reduce viral excre�on caused by canine parainfluenza virus

Onset of immunity:l 3 weeks a�er the first vaccina�on for CDV, CAV, CPV,

given with compa�ble product Biocan Novel DHPPi/L4 and the vaccina�on scheme planned accordingly (please refer to SPC for Biocan Novel DHPPi/L4).

Revaccina�on scheme:A single dose of Biocan Novel DHPPi should be given every 3 years. Annual re-vaccina�on is required for Parainfluenza, therefore a single dose of Biocan Novel DHPPi or Biocan Novel Pi/L4 can be used annually if required. Full protec�ve immunity against leptospira component of the Pi/L4 vaccine, if used for annual revaccina�on, is formed only a�er the basic vaccina�on with a Biocan Novel vaccine containing the L4 component.

SHELF LIFE 24 months, a�er recons�tu�on according to direc�ons: administer the vaccine immediately.

STORAGE Store and transport refrigerated (2 °C – 8 °C). Do not freeze

PACKAGE10 × 1 dose, 25 × 1 dose.

28

Biocan NOVEL DHPPi lyophilisate and solvent for suspension for injec�on for dogs

1 Canine vaccines

l 3 weeks a�er comple�on of the primary course for CPiV

Dura�on of immunity:At least three years following the primary vaccina�on course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus. At least one year following the primary vaccina�on course for canine parainfluenza virus.The dura�on of immunity against CAV-2 was not established by challenge. It was shown that 3 years a�er the vaccina�on CAV-2 an�bodies are s�ll present. Protec�ve immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.

DOSAGE AND METHOD OF ADMINISTRATIONSubcutaneous use

Dose and route of administra�on:Asep�cally recons�tute the lyophilisate with the solvent. Shake well and administer immediately the en�re content (1 ml) of the recons�tuted product.

Basic vaccina�on scheme:Two doses of Biocan Novel DHPPi apart 3–4 weeks apart from 6 weeks of age.

If protec�on against leptospira is required the second dose may be

Combined vaccine containing four the most common and highly pathogenic serovars of Leptospira spp. in diluent frac�on

COMPOSITIONFreeze-dried frac�on (live a�enuated):Canine Distemper virus, strain CDV Bio 11/A,

3.1 5.1min. 10 max. TCID 10 TCID 50 50Canine Adenovirus Type 2, strain CAV-2-Bio 13,

3.6 5.3min. 10 TCID max. 10 TCID50 50Canine Parvovirus Type 2b, strain CPV-2b-Bio 12/B,

4.3 6.6min. 10 TCID max. 10 TCID50 50Canine Parainfluenza virus, strain CPiV-Bio 15,

3.1 5.1min. 10 TCID max. 10 TCID50 50Liquid frac�on (inac�vated): Leptospira interrogans, serogroup Icterohaemorrhagiae,serovar Icterohaemorrhagiae, kmen MSLB 1089 GMT ≥ 1:51 ALRLeptospira interrogans, serogroup Canicola, serovar Canicola, kmen MSLB 1090 GMT ≥ 1:51 ALRLeptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, kmen MSLB 1091 GMT ≥ 1:40 ALRLeptospira interrogans, serogroup Australis, serovar Bra�slava, kmen MSLB 1088 GMT ≥ 1:51

INDICATIONAc�ve immuniza�on of dogs from 6 weeks of age:to prevent mortality and clinical signs caused by canine distemper virus

Primary vaccina�on scheme:Two doses of Biocan Novel DHPPi/L4 3–4 weeks apart from 6 weeks of age.

Rabies:If protec�on against rabies is required:

First dose: Biocan Novel DHPPi/L4 from 8–9 weeks of age.Second dose: Biocan Novel DHPPi/L4R 3–4 weeks later, but not before 12 weeks of age. In case of need, dogs younger than 8 weeks can be vaccinated as safety of Biocan Novel DHPPi/L4R has been demonstrated in 6 weeks old dogs.Revaccina�on scheme:A single dose of Biocan Novel DHPPi/L4 should be given every 3 years. Annual re-vaccina�on is required for Parainfluenza and Leptospira components, therefore a single dose of compa�ble vaccine Biocan Novel Pi/L4 can be used annually as required.

SHELF LIFE 24 months, a�er recons�tu�on according to direc�ons: administer the vaccine immediately.

STORAGEStore and transport refrigerated (2 °C – 8 °C). Do not freeze.


29

Biocan NOVEL DHPPi/L4lyophilisate and solvent for suspension for injec�on for dogs

1 Canine vaccines

to prevent mortality and clinical signs caused by canine adenovirus type 1to prevent clinical signs and reduce viral excre�on caused by canine adenovirus type 2to prevent clinical signs, leukopenia and viral excre�on caused by canine parvovirus to prevent clinical signs (nasal and ocular discharge) and reduce viral excre�on caused by canine parainfluenza virusto prevent clinical signs, infec�on and urinary excre�on caused by L. interrogans serogroup Australis serovar Bra�slavato prevent clinical signs and urinary excre�on and reduce infec�on caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterhaemorrhagiae serovar Icterohaemorrhagiaeto prevent clinical signs and reduce infec�on and urinary excre�on caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa

DOSAGE AND METHOD OF ADMINISTRATION Subcutaneous use.Dose and route of administra�on:Asep�cally recons�tute the lyophilisate with the solvent. Shake well and administer immediately the en�re content (1 ml) of the recons�tuted product.

Polyvalent vaccine intended for the last revaccina�on of puppies and boostering adult dogs

COMPOSITIONFreeze-dried frac�on (live a�enuated): Canine Distemper virus,

3.1strain CDV Bio 11/A – min. 10 TCID 505.1max. 10 TCID , Canine Adenovirus 50

3.6Type 2, strain CAV-2-Bio 13 – min. 10 5.3TCID max. 10 TCID , Canine 50 50

Parvovirus Type 2b, strain CPV-2b-Bio 4.3 6.612/B – min. 10 TCID max. 10 50

TCID , Canine Parainfluenza virus, 503.1 50strain CPiV-Bio 15 – min. 10 TCID

50max. 10 TCID5.1Liquid frac�on (inac�vated):Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, kmen MSLB 1089 GMT ≥ 1:51 ALRLeptospira interrogans, serogroup Canicola, serovar Canicola, kmen MSLB 1090 GMT ≥ 1:51 ALRLeptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, kmen MSLB 1091 GMT ≥ 1:40 ALRLeptospira interrogans, serogroup Australis, serovar Bra�slava, kmen MSLB 1088 GMT ≥ 1:51Inac�vated rabies virus, strain SAD Vnukovo-32 > 2.0 IU

INDICATIONAc�ve immuniza�on of dogs from 8–9 weeks of age:to prevent mortality and clinical signs caused by canine distemper virusto prevent mortality and clinical signs caused by canine adenovirus type 1

recons�tute the lyophilisate with the solvent. Shake well and administer immediately the en�re content (1 ml) of the recons�tuted product.

Basic vaccina�on scheme:Two doses of Biocan Novel DHPPi/L4R 3–4 weeks apart from 8–9 weeks of age. The second dose should not be given before 12 weeks of age.

RabiesIn case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6 weeks old dogs. The vaccina�on may be indicated as soon as 6 weeks of age with compa�ble product Biocan Novel DHPPi.

Revaccina�on scheme:A single dose of Biocan Novel DHPPi/ L4R should be given every 3 years. Annual re-vaccina�on is required for Parainfluenza and Leptospira components therefore a single dose of compa�ble vaccine Biocan Novel Pi/L4 can be used annually as required.

SHELF LIFE24 months, a�er recons�tu�on according to direc�ons: administer the vaccine immediately.

STORAGEStore and transport refrigerated (2 °C – 8 °C).Do not freeze. Protect from light.


30

Biocan NOVEL DHPPi/L4Rlyophilisate and solvent for suspension for injec�on for dogs

1 Canine vaccines

to prevent clinical signs and reduce viral excre�on caused by canine adenovirus type 2, to prevent clinical signs, leukopenia and viral excre�on caused by canine parvovirus to prevent clinical signs (nasal and ocular discharge) and reduce viral excre�on caused by canine parainfluenza virus, to prevent clinical signs, infec�on and urinary excre�on caused by L. interrogans serogroup Australis serovar Bra�slavato prevent clinical signs and urinary excre�on and reduce infec�on caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiaeto prevent clinical signs and reduce infec�on and urinary excre�on caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosato prevent mortality, clinical signs and infec�on caused by rabies virus

Dura�on of immunity:At least three years following the primary vaccina�on course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and rabies. At least one year following the primary vaccina�on course for canine parainfluenza virus, Leptospira components.

DOSAGE Subcutaneous use. Asep�cally

Vaccine intended for yearly revaccina�on against parainfluenza and leptospirosis

COMPOSITIONFreeze-dried frac�on (live a�enuated):Canine Parainfluenza virus, strain

3.1CPiV-Bio 15 min 10 TCID 505.1max. 10 TCID50

Liquid frac�on (inac�vated):Leptospira interrogans, serogroup Icterohaemorrhagiae,serovar Icterohaemorrhagiae, kmen MSLB 1089 GMT ≥ 1:51 ALRLeptospira interrogans, serogroup Canicola, serovar Canicola, kmen MSLB 1090 GMT ≥ 1:51 ALRLeptospira kirschneri, serogroup Grippotyphosa, serovar Grippotyphosa, kmen MSLB 1091 GMT ≥ 1:40 ALRLeptospira interrogans, serogroup Australis,serovar Bra�slava, kmen MSLB 1088 GMT ≥ 1:51Lyophilisate and solvent, for suspension for injec�on.The visual appearance is as follows:

DOSAGE Recons�tute one vial of the lyophilisate asep�cally using the contents of one vial of the solvent. Shake well and immediately inject the en�re content of the recons�tuted vial (1 ml) subcutaneously. Do not use chemically sterilised syringes or needles, as these may interfere with the effec�veness of the vaccine.Basic vaccina�on scheme:Two doses of Biocan Novel Pi/L4 3 – 4 weeks apart from 6 weeks of age.Revaccina�on scheme:A single dose of Biocan Novel Pi/L4 to be given annually.


STORAGEStore and transport refrigerated (2 °C – 8 °C). Do not freeze.


31

Biocan NOVEL Pi/L4lyophilisate and solvent for suspension for injec�on for dogs

1 Canine vaccines

Lyophilisate: Spongy ma�er of white colour.Solvent: Whi�sh colour with easily shakeable sediments.Recons�tuted vaccine: Pinkish or yellowish colour with light opalescence

INDICATIONAc�ve immuniza�on of dogs from six weeks of age.- to prevent clinical signs and reduce viral excre�on caused by canine parainfluenza virus- to prevent clinical signs, infec�on and urinary excre�on caused by Leptospira serovars bra�slava, canicola, grippotyphosa and icterohaemorrhagiaeOnset of immunity:Immunity has been demonstrated from 3 weeks a�er comple�on of the primary course for CPiV and from 4 weeks a�er comple�on of the primary course for Leptospira components.Dura�on of immunity:At least one year following the primary vaccina�on course for all components of Pi/L4.

Monovalent rabies vaccine containing �me-tested strain SAD Vnukovo - 32

COMPOSITIONLiquid frac�on (inac�vated):Inac�vated rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU***Adjuvant:Aluminium hydroxide gel 1.8–2.2 mgINDICATIONAc�ve immuniza�on of dogs from 12 weeks of age to prevent mortality, clinical signs and infec�on caused by rabies virus.In case of need, dogs younger than 12 weeks can be vaccinated. In this case the vaccine can be administered from 6 weeks of age in two doses. The second dose should not be administered before 12 weeks of age and not earlier than 3 weeks a�er the first dose.

Onset of immunity:2 weeks a�er a single vaccina�on from 12 weeks of age.

Dura�on of immunity:At least three years following the primary vaccina�on course. Dura�on of immunity was demonstrated a�er one vaccina�on at 12 weeks of age.

In case of need, dogs younger than 12 weeks can be vaccinated. In this case the vaccine can be administered from 6 weeks of age in two doses. The second dose should not be administered before 12 weeks of age and not earlier than 3 weeks a�er the first dose.

Revaccina�on scheme:A single dose of Biocan Novel R should be given every 3 years.


SPECIAL STORAGE PRECAUTIONStore and transport refrigerated (2 °C – 8 °C). Do not freeze.


32

Biocan NOVEL R

1 Canine vaccines

DOSAGE1 ml subcutaneously. Do not use chemically sterilised syringes or needles, as these may interfere with the effec�veness of the vaccine. Shake well before administra�on.Basic vaccina�on scheme:One dose of Biocan Novel R from 12 weeks of age.The efficacy is proven a�er a single dose from 12 weeks of age in laboratory studies.

However, in field studies 10% of seronega�ve dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks a�er single primary vaccina�on against rabies. Another 17% did not show the 0.5 IU/ml rabies an�body �tre required by some non-EU countries to travel in. In case of travelling to risk areas or for travel outside the EU veterinary surgeons may wish to use a two dose primary course including rabies or give an addi�onal rabies vaccina�on a�er 12 weeks.

NOVELTY 2017

33

BioBos IBR marker inact.

BioBos IBR marker liveBioBos L

BioBos L(6)BioBos Respi 2 intranasal

BioBos Respi 3BioBos Respi 4

KOLIBIN RC NeoMORAXEBIN Neo

TRICHOBENTRICHOBEN AV

CATTLE VACCINES

2

34

Marker vaccine against IBR (BHV-1) inac�vated

COMPOSITIONAc�ve substance:Bovine herpesvirus type 1 (BHV-1) inac�vated (strain Bio-27: IBR gE -) RP ≥ 1

TARGET SPECIESCa�le from the age of 3 months.

INDICATION For ac�ve immuniza�on of ca�le to reduce intensity and term of the clinical symptoms caused by infec�on by the BHV-1 (IBR) virus and to reduce excre�on of the field virus.

STORAGEStore in a refrigerator (2 °C – 8 °C). Do not freeze.

PACKAGE10 ml, 50 ml, 100 ml in glass or plas�c bo�le.

BioBos IBR marker inact.

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage: 2 mlApplica�on: intramuscularly.Basic vaccina�on: two applica�ons in the 3-week interval.Revaccina�on: one applica�on every 6 months.

Onset of protec�on 3 weeks a�er the basic vaccina�on immunity persists 6 months a�er the basic vaccina�on.

SHELF LIFE Shelf life of the veterinary medicinal product in intact package 2 years and a�er the first opening of the immediate packaging 10 hours.

injec�on suspension for ca�le

35

Marker vaccine against IBR (BHV- 1) live

COMPOSITIONAc�ve substance:Bovine herpesvirus type 1 (BHV-1) a�enuated (strain Bio-27: IBR

5.7gE -) min. 10 TCID50; 7.5max. 10 TCID50

TARGET SPECIESCa�le.

DOSAGE AND ROUTE OF ADMINISTRATION2 ml intranasal or intramuscularly a�er asep�c prepara�on of the vaccine.


PACKAGE5 × 5 doses or 1 × 25 doses in glass vials with 10 ml or 50 ml Diluent A.

BioBos IBR marker live

2 Ca�le vaccines

CHARACTERISTIC AND INDICATION Marker vaccine against IBR (BHV-1) live for the ac�ve immuniza�on of ca�le from 2 weeks of age, to reduce the intensity and dura�on of clinical symptoms induced by viral infec�on caused by BHV-1 (IBR), and to decrease the excre�on of field virus. The onset of immunity was demonstrated 7 days a�er intranasal vaccina�on and 14 days a�er intramuscular vaccina�on of serologically nega�ve animals. The vaccine does not induce the forma�on of an�bodies against IBR glycoprotein E (marker vaccine). Thereby ca�le vaccinated using this vaccine can be recognized from ca�le infected with IBR field virus or vaccinated using conven�onal non-marker vaccines against IBR virus.

lyophilizate and solvent for prepara�on of suspension

36

Inac�vated monovalent vaccine against leptospirosis of ca�le caused by Leptospira borgpetersenii serovar hardjo, type hardjo-bovis

COMPOSITIONAc�ve substance:Leptospira hardjo type hardjo-bovis inact. min. �tre 32 determined by ALR*

* The value was determined on the basis of the �tres of the reference serum obtained from 5 rabbits vaccinated with a batch compliant with the challenge potency test on the target species (ALR = agglu�na�on-ly�c reac�on).


INDICATION For ac�ve immuniza�on of ca�le since 4 weeks of age against leptospirosis (serovar hardjo, typ. hardjo-bovis) to prevent infec�on, protec�on of embryos and foetuses and excre�on of leptospiras especially by urine.

Revaccina�on:For the keeping of the protec�ve immunity an annual revaccina�on by a single dose is required at least 2 weeks before ma�ng.Onset imunity 4 weeks a�er basic vaccina�on scheme (a�er two doses of vaccine) and dura�on of immunity 12 months.

SHELF LIFEShelf life of the veterinary medicinal product in intact package 2 years and a�er the first opening of the immediate packaging 10 hours.


PACKAGE4 ml, 10 ml, 20 ml, 50 ml, 100 ml, 250 ml in glass or plas�c HDPE bo�le.

BioBos L

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage: 2 mlApplica�on: subcutaneously

Basic vaccina�on:This requires administra�on of 2 vaccina�on doses with the range of 4 – 6 weeks, whereas the second dose must be administered at least 4 weeks before ma�ng. The main effect is the preven�on of excre�on of leptospiras by urine. If the second vaccina�on dose is administered at least 2 weeks before ma�ng the significant preven�on of the foetus also occurs.The calves may be vaccinated from 4 weeks of age, the basic vaccina�on requires the administra�on of 2 vaccina�on doses. At reaching the category of the heifer the vaccina�on is accomplished once before ma�ng.


37

Inac�vated polyvalent vaccine against leptospirosis of ca�le caused by major dangerous 6 serovars

COMPOSITIONAc�ve substance:Leptospira pomona inact. min. �tre 16 determined by ALR*Leptospira hardjo type hardjo-prajitno inact. min. �tre 35 determined by ALR*Leptospira hardjo type hardjo-bovis inact. min. �tre 32 determined by ALR*Leptospira grippotyphosa inact. min. �tre 64 determined by ALR*Leptospira icterohaemorrhagiae inact. min. �tre 81 determined by ALR*Leptospira canicola inact. min. �tre 35 determined by ALR*

* The values were determined on the basis of the �tres of the reference serum obtained from 5 rabbits vaccinated with a batch compliant with the challenge potency test on the target species (ALR = agglu�na�on-ly�c reac�on).


doses. At reaching the category of the heifer the vaccina�on is accomplished once before ma�ng. Revaccina�on: For the keeping of the protec�ve immunity an annual revaccina�on by a single dose is required at least 2 weeks before ma�ng.Onset imunity 4 weeks a�er basic vaccina�on scheme ( a�er two doses of vaccine) and dura�on of immunity 12 months.


STORAGE Store in a refrigerator (2 °C – 8 °C). Do not freeze.

PACKAGE10 ml, 50 ml, 100 ml in glass or plas�c bo�les.

BioBos L(6)

2 Ca�le vaccines

INDICATION For ac�ve immunisa�on of ca�le from 4 weeks of age against leptospirosis (6 serovars contained in the vaccine) to prevent infec�on, foetal infec�on and elimina�on of leptospires especially in urine.


Basic vaccina�on:This requires administra�on of 2 vaccina�on doses with the range of 4 – 6 weeks, whereas the second dose must be administered at least 4 weeks before ma�ng. The main effect is the preven�on of excre�on of leptospiras by urine. If the second vaccina�on dose is administered at least 2 weeks before ma�ng the significant preven�on of the foetus also occurs.The calves may be vaccinated from 4 weeks of age, the basic vaccina�on requires the administra�on of 2 vaccina�on


38

Intranasal live vaccine against major viral pathogens of Bovine respiratory disease complex (BRDC) caused by Bovine respiratory syn��al virus and Parainfluenza 3 virus

COMPOSITIONAc�ve substance:Bovine parainfluenza 3 (PI3), modified live virus, strain Bio

5.0 7.523/A 10 – 10 TCID50Bovine respiratory syncy�al virus (BRSV), modified, live, strain Bio

4.0 6.024/A 10 – 10 TCID50

50TCID – a 50% infec�ous dose for �ssue cultures

TARGET SPECIESCa�le from the age of 10 days

INDICATION For the ac�ve immuniza�on of calves from the age of 10 days against BRSV and PI3V, to reduce the amount and dura�on of excre�on of both these viruses.

STORAGEStore in a refrigerator (2 °C – 8 °C). Do not freeze. Protect from direct sunlight.

PACKAGEPrinted carton: 1 × 5 doses (1 × 3 ml of lyophilised vaccine + 1×10 ml of Diluent A). Plas�c box with a lid, with 10 wells: 5 × 5 doses (5 × 3 ml of lyophilised vaccine + 5 × 10 ml of Diluent A). Intranasal applicator (box with 5 pieces) is not part of the packaging. Aplicators are distributed together with the vaccine.

BioBos Respi 2 intranasal

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage: 2 mlApplica�on: intranasally

Administer one dose (2 ml) of the diluted vaccine intranasally to calves from 10 days of age using an special intranasal applicator. It is recommended to use a new applicator for each animal, in order to prevent the transmission of infec�on. The onset of immunity has been demonstrated 10 days a�er a single vaccina�on. The dura�on of immunity a�er single dose is 12 weeks. Immunity has been demonstrated by vaccina�on of serologically nega�ve animals.

SHELF LIFE Shelf life of the veterinary medicinal product in intact package (lyophilisate) 2 years and solvent as packaged for sale 4 years. Shelf life a�er dilu�on according to direc�ons: 2 hours.

lyophilisate and solvent for nasal suspension

39

Inac�vated vaccine against Bovine respiratory disease complex (BRDC) caused by Bovine respiratory syncy�al virus, Parainfluenza 3 virus and bacteria Mannheimia (Pasteurella) haemoly�ca

COMPOSITIONAc�ve substance:Virus respiratoris syncy�alis bovis inac�vatum, strain Bio-24 RP ≥ 1*Virus parainfluensis 3 bovis inac�vatum, strain Bio-23 RP ≥ 1*Mannheimia (Pasteurella) haemoly�ca inac�vata, strain DSM 5283, serovar 1A RP ≥ 1*

*) Rela�ve efficiency (RP) is given by the comparison of the an�body levels in serum prepared with the reference vaccine batch complying with the challenge test in target animals.

TARGET SPECIESCa�le from the age of 2 weeks.

INDICATION For ac�ve immunisa�on of ca�le against Parainfluenza 3 virus to reduce infec�on, Bovine respiratory syncy�al virus to reduce infec�on and clinical symptoms, and bacteria Mannheimia (Pasteurella) haemoly�ca serotype A1 to reduce clinical symptoms and pulmonary lesions.

An�body response against BRS virus, PI 3 virus and Mannheimia haemoly�ca reaches the highest level in 3 weeks a�er full immunisa�on programme. Another revaccina�on is recommended as required within an interval of 6 months a�er performance of the basic immunisa�on, because immunity persists a�er revaccina�on for at least 6 months.



PACKAGE2 ml, 10 ml, 20 ml, 50 ml, 100 ml in glass bo�le.

BioBos Respi 3

2 Ca�le vaccines


Basic immunisa�on (vaccina�on with subsequent revaccina�on): Vaccina�on of calves is recommended from 8 weeks of age with revaccina�on in 2–4 weeks (it is possible to vaccinate calves from the age of 2 weeks).

Revaccina�on: In problema�c breeds, another revaccina�on is recommended within a period of 6 months a�er basic immunisa�on, possibly before risky period in par�cular breed (e.g. transfer of animals, change of the stabling system, etc.). Pregnant cows and heifers: Vaccina�on with subsequent revaccina�on within 7–5 weeks and 4–2 weeks before expected date of labour due to increased resistance of the offspring via colostrum.


40

Inac�vated vaccine against Bovine respiratory disease complex (BRDC) caused by Bovine respiratory syncy�al virus, Parainfluenza 3 virus, Bovine viral diarrhoea virus and bacteria Mannheimia (Pasteurella) haemoly�ca

COMPOSITIONAc�ve substance:Virus respiratoris syncy�alis bovis inac�vatum,

strain BIO-24 RP ł 1 Virus parainfluensis 3 bovis inac�vatum,

strain BIO-23 RP ł 1Virus diarrhoeae bovis inac�vatum,

strain BIO-25 RP ł 1 Mannheimia (Pasteurella) haemoly�ca inac�vata, strain DSM 5283,

serovar 1A RP ł 1

The vaccine induces produc�on of an�bodies against infec�on caused by Bovine respiratory syn��al virus, Parainfluenza 3 virus, Bovine viral diarrhoea virus and bacteria Mannheimia (Pasteurella) haemoly�ca.

TARGET SPECIESCa�le from the age of 2 weeks.

INDICATION For ac�ve immunisa�on of ca�le against Parainfluenza 3 virus to reduce infec�on, Bovine respiratory syncy�al virus to reduce infec�on and clinical

Pregnant cows and heifers: Vaccina�on with subsequent revaccina�on within 7 – 5 weeks and 4 – 2 weeks before expected date of labour due to increased resistance of the offspring via colostrum.An�body response against BRS virus, PI 3 virus, BVD virus and Mannheimia haemoly�ca reaches the highest level in 3 weeks a�er full immunisa�on programme. Another revaccina�on is recommended as required within an interval of 6 months a�er performance of the basic immunisa�on, because immunity persists for at least 6 months.

SHELF LIFEShelf life of the veterinary medicinal product in intact package 2 years and a�er the first opening of the immediate packaging 10 hours.


PACKAGE2 ml, 10 ml, 20 ml, 50 ml, 100 ml in glass bo�le.

BioBos Respi 4

2 Ca�le vaccines

symptoms, Bovine viral diarrhoea virus to reduce infec�on, and bacteria Mannheimia (Pasteurella) haemoly�ca serotype A1 to reduce clinical symptoms and pulmonary lesions.


Basic immunisa�on (vaccina�on with subsequent revaccina�on): Vaccina�on of calves is recommended from 8 weeks of age with revaccina�on in 2–4 weeks (it is possible to vaccinate calves from the age of 2 weeks).

Revaccina�on: In problema�c breeds, another revaccina�on is recommended within a period of 6 months a�er basic immunisa�on, possibly before risky period in par�cular breed (e.g. transfer of animals, change of the stabling system, etc.).


41

Inac�vated vaccine against rota, corona and coli-infec�ons of calves

COMPOSITIONAc�ve substance:Rotavirus bovinum,

strain TM-91, inact. RP ł 1Coronavirus bovinum,

strain C-197, inact. RP ł 1E. coli – 3 serovars of inac�vated enteropathogenic strains – O8:K35, K99; O9:K35, K99;

O101:K30, K99 RP ł 1

Vaccina�on of pregnant heifers and cows induces forma�on of the specific colostral an�bodies against both the viral and bacterial an�gens contained in the vaccine.

TARGET SPECIESCa�le (pregnant heifers and cows).

INDICATION Ac�ve immunisa�on of pregnant heifers and cows for the purpose of passive immunisa�on of calves against gastro-enteric diseases caused by rotavirus, coronavirus and enteropathogenic E. coli strains.

lactogenic immunity for the first 2–4 weeks of life. Feeding with colostrum:In order to ensure the effec�ve preven�on of calves against infec�on, the gastrointes�nal tract of calves shall be saturated with colostrum obtained from the vaccinated cows for the first 2–3 weeks of their life. A calf shall drink the adequate colostrum volume obtained from the vaccinated cows within 6 hours a�er its birth.



PACKAGE2 ml, 4 ml, 10 ml, 20 ml, 50 ml, 100 ml, 250 ml in glass bo�le.

KOLIBIN RC Neo

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage: 2 mlApplica�on: intramuscularly,preferably into the muscles in gluteal region

The pregnant heifers (or s�ll unvaccinated cows) are vaccinated twice at the interval of 21 days, namely, 7–5 weeks and 4–2 weeks before the first expected calving.The next vaccina�ons are performed once, namely, before each next calving.

Onset of immunity in calves fed from mothers , and in calves fed with colostrum collected from the vaccinated cows, the passive protec�on starts when feeding begins. Dura�on of imunity in calves fed with colostrum collected from the vaccinated cows, their passive protec�on against infec�on lasts un�l feeding with colostrum is interrupted. The calves fed from mothers are protected against the infec�on by colostral and


42

Inac�vated vaccine against bovine infec�ous keratoconjunc�vi�s caused by Moraxella bovis

COMPOSITIONAc�ve substance:Moraxella bovis inac�vata – at

10least 2.5 × 10 CFU


INDICATION Immunoprophylaxis of infec�ous bovine keratoconjunc�vi�s in ca�le aged 1 months and above. From the immunological point of view, the mass vaccina�on should be performed in all sensi�ve animals before the beginning of a grazing season.

SHELF LIFEShelf life of the veterinary medicinal product in intact package 18 months and a�er the first opening 10 hours.

STORAGEKeep in a dry and dark place at of 2 to 8 °C. Do not freeze!

PACKAGE 10 ml, 20 ml, 50 ml, 100 ml, 250 ml, 500 ml in glass or plas�c bo�le.

MORAXEBIN Neo

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage: 2 mlApplica�on: intramuscularly2× at an interval of 14 daysinto a neck musculature close to a lymph-node before a blade-bone.

A�er the an�gen contained in the vaccine is applied into an animals body, the specific an�bodies against the infec�ous keratoconjunc�vi�s are formed and protect the immunized animal against the disease men�oned.

Onset of immunity is 14 days a�er the vaccina�on and lasts for 9 months.


43

Live vaccine for preven�on and treatment of bovine trichophytosis caused by Trichophyton verrucosum

COMPOSITIONAc�ve substance:A) Lyophilizate: Trichophyton

6verrucosum – min. 3,125 × 10 6CFU, max. 18,75 × 10 CFU

B) Solvent: Diluent A

TARGET SPECIESCa�le from one day of age.

INDICATION Both the preven�on and treatment of bovine trichophytosis. All animals in the stables must be vaccinated. Vaccina�on is also necessary a�er storing all newly stopped 1–2 month calves and animals transferred, since Trichophyton verrucosum is very resistant and survives in the environment for 6–8 years.

Immunity of the cellular type and par�ally of the humoral type is induced in the immunized animals. Onset of immunity is 1 month a�er the revaccina�on and lasts at least 5 years.

WITHDRAWAL PERIODSMeat: 14 days.

SHELF LIFE3 years. The vaccine shall be consumed within 2 hours since its dissolu�on.

STORAGEStore and transport refrigerated (2 °C – 8 °C). Protect from frost. Protect from light.

PACKAGE5 × 10 ml, 1 × 40 ml in glass bo�le.

TRICHOBEN

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage (prophylac�c and therapeu�c):Calves aged one day up to three months ………… 2 × 2 mlCa�le older than three months …… 2 × 4 mlThe interval between the vaccina�on and the revaccina�on should be 5–14 days.

Applica�on: Intramuscular at the lumbar or gluteal region.

For vaccina�on and revaccina�on is recommended alterna�ng right and le� sides of the bodyAnother (the third) revaccina�on can be performed 2–4 weeks a�er the revaccina�on in the animals affected heavily with trichophy�c changes and also in cachec�c animals.

lyophilisate and solvent for prepara�on of injec�on suspension for ca�le

44

Avirulent live vaccine for preven�on and treatment of bovine trichophytosis caused by Trichophyton verrucosum

COMPOSITIONAc�ve substance:A) Lyophilizate: Trichophyton verrucosum avirulentum –

6 min. 3,125 × 10 CFU6 max. 18,75 × 10 CFU

B) Solvent: Diluent A

TARGET SPECIESCa�le from one day of age.

INDICATION For ac�ve immunisa�on of ca�le to reduce clinical signs of dermatophytosis caused by Trichophyton verrucosum for prophylac�c vaccina�on and for therapeu�c use. All animals in the stables must be vaccinated. Vaccina�on is also necessary a�er storing all newly stopped 1–2 month calves and animals transferred, since Trichophyton verrucosum is very resistant and survives in the environment for 6–8 years.

WITHDRAWAL PERIODSMeat: 14 days.

SHELF LIFE 3 years. The vaccine shall be consumed within 2 hours since its dissolu�on.

STORAGEStore and transport refrigerated (2 °C – 8 °C). Protect from frost. Protect from light.

PACKAGE5 × 10 ml, 1 × 40 ml in glass bo�le.

TRICHOBEN AV

2 Ca�le vaccines

DOSAGE, ROUTE OF ADMINISTRATION AND VACCINATION SCHEME Dosage (prophylac�c and therapeu�c):Calves aged one day up to three months ... 2 × 2 mlCa�le older than three months ... 2 × 4 mlThe interval between the vaccina�on and the revaccina�on should be 5–14 days.

Applica�on: Intramuscular at the lumbar or gluteal region. For vaccina�on and revaccina�on is recommended alterna�ng right and le� sides of the bodyAnother (the third) revaccina�on can be performed 2–4 weeks a�er the revaccina�on in the animals affected heavily with trichophy�c changes and also in cachec�c animals.

Immunity is created within 1 month a�er revaccina�on and it persists at least one year.

lyophilisate and solvent for prepara�on of injec�on suspension for ca�le

45

BioEquin F BioEquin FHBioEquin FT BioEquin H CLOTEID 4 FLUEQUIN

FLUEQUIN T TRICHOEQUEN

EQUINE VACCINES

3

46

Novel vaccine containing influenza an�gens in according with the epidemiological situa�on

COMPOSITIONAc�ve substances in one doseVirus influenzae equorum inac�vatum, strains:A/Equi 2/Morava 95

1(European type) min. 5 log HIT2A/Equi 2/Brno 08 (American type,

1clade Florida 2) min. 5 log HIT21 geometrical average of specific an�bodies determinated by heamagglu�na�on inhibi�on test in serum of guinea pigs

Injec�on suspension.

TARGET SPECIESHorse.

INDICATION For ac�ve immuniza�on of horses to reduce the occurrence of clinical signs caused by equine influenza virus and to reduce virus spreading a�er infec�on. Onset of immunity: 14 days a�er primary vaccina�onDura�on of immunity: 6 months a�er primary vaccina�on and 12 months a�er third dose of vaccina�on

SHELF LIFE33 months, a�er the first opening in more doses: 10 hours.

STORAGE Store in a refrigerator (2 °C – 8 °C).


BioEquin F, suspension for injec�on for horses

3 Equine vaccines

DOSAGE1 ml deep intramuscularly.

Primary vaccina�on courseFirst injec�on at the age 6 months, second injec�on is made 4 weeks later.

Revaccina�onThe first revaccina�on (third dose) is given 6 months a�er the primary vaccina�on course and further revaccina�on against influenza is carried out once in 12 months.Revaccinate pregnant mares in the last trimester of pregnancy, no later than one month before the planned delivery.

Vaccines against influenza

47

Unique combina�on of current influenza an�gens and highly immunogenic strain of EHV-1

COMPOSITIONAc�ve substances in one dose:Virus influenzae equorum inac�vatum, strain:A/Equi 2/Brno 08 (American

1type) H3N8 min. 6.0 log2 HITA/Equi 2/ Morava 95 (European

1type) H3N8 min. 6.0 log2 HITHerpesvirus equorum inac�vatum (EHV-1)

2 min. 2.1 log10 VNIAdjuvant(s): Oil adjuvant (Montanide ISA 35 VG) 0.25 ml

Emulsion for injec�on. The vaccine is a white, oily liquid with easily shakeable sediment.

TARGET SPECIESHorses.

INDICATION For ac�ve immuniza�on of horses to reduce the occurrence of respiratory infec�on and clinical signs caused by equine influenza virus and equine herpesvirus (EHV-1).

Revaccina�on against equine influenza and herpesvirus: The first revaccina�on (third dose) is administered 3 months a�er the primary vaccina�on and next revaccina�on is carried out every 6 months.

Vaccina�on of pregnant mares:To reduce the incidence of abor�ons caused by equine herpesvirus infec�on one dose of the vaccine is administered to pregnant mares in the second month a�er ma�ng and then in the fi�h or sixth month and in the ninth month of pregnancy.

SHELF LIFEShelf-life of the veterinary medicinal product as packaged for sale: 18 months.Shelf-life a�er first opening the immediate packaging: 10 hours.

STORAGE Store in a refrigerator (2 °C – 8 °C). Protect from light. Store in a dry place.


BioEquin FH

3 Equine vaccines

For ac�ve immuniza�on to reduce the occurrence of abor�ons in pregnant mares caused by equine herpesvirus (EHV-1) infec�on.

Onset of ac�ve immunity: 14 days a�er primary vaccina�on

Dura�on of ac�ve immunity: 6 months a�er revaccina�on.

DOSAGEVaccine dose – 1 ml. The vaccine (1 ml) is applied deep intramuscularly.Before use heat the contents of the vial to a temperature of 15–25 °C and shake well.

Vaccina�on schedule:Primary vaccina�on against equine influenza and herpesvirus:The first vaccina�on at the age of 6 months; the second vaccina�on 4 weeks later.

emulsion for injec�on for horses

48

Effec�ve combina�on of current influenza an�gens and purified tetanus toxoid

BioEquin FT

3 Equine vaccines

emulsion for injec�on for horses

COMPOSITIONAc�ve substances in one vaccine dose (1 ml) contains:Inac�vated virus equine influenza, strain:A/Equi 2/ Morava 95 (European

1type), H3N8 min. 5 log HIT2A/Equi 2/Brno 08 (American type,

1Florida 2), H3N8 min. 5 log HIT2

2Tetanus toxoid purified min. 30 IU1. geometrical average of specific an�bodies determinated by heamagglu�na�on inhibi�on test in serum of guinea pigs 2. Interna�onal Units; �tre of an�bodies against toxin induced a�er repeted vaccian�on of guinea pigs determined by ELISA method

Adjuvant(s): Aluminium hydroxide hydrated for adsorp�on 0.2 ml

Suspension for injec�on. White or yellowish to greyish brown suspension, during storage se�le down sediment disperses a�er shaking.


INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For ac�ve immuniza�on of horses from 6 months of age against equine influenza to reduce clinical signs and excrec�on a�er infec�on, and ac�ve immunisa�on against tetanus.

Revaccina�on: The first revaccina�on is administered 6 months a�er the primary vaccina�on and next revaccina�on is carried out every 12 months. Revaccina�on of pregnant mares in the last trimester of pregnancy is carried out no later than one month before the planned parturi�on.It is not recommended to use the vaccine BioEquin FT for the revaccina�on of horses previously vaccinated with the vaccine from another manufacturer or revaccinated the vaccine BioEquin FT by the vaccine of the another manufacturer. Vaccines containing the same strains of equine influenza as BioEquin FT are excep�ons.

SHELF LIFEShelf-life of the veterinary medicinal product as packaged for sale: 33 months. Shelf-life a�er first opening the immediate packaging: 10 hours.

STORAGE Store in a refrigerator (2 °C – 8 °C).Protect from frost. Protect from light. Store in a dry place.

PACKAGE2 × 1 dose, 10 × 1 dose

Onset of immunity has been demonstrated by challenge test for equine influenza strain A/Equi 2/Brno 08, and by serology for strain A/Equi 2/Morava 95.Dura�on of immunity has been demonstrated by serology for both vaccine influenza strains. Influenza: Onset of ac�ve immunity: 14 days a�er primary vaccina�onDura�on of ac�ve immunity: 6 months a�er primary vaccina�on and at least 12 months a�er the first revaccina�on (a�er the third dose).Tetanus: Onset of ac�ve immunity: 14 days a�er primary vaccina�onDura�on of ac�ve immunity: 6 months a�er primary vaccina�on and at least 12 months a�er the first revaccina�on (a�er the third dose).

DOSAGE AND ADMINISTRATION ROUTEVaccine dose – 1 ml. The vaccine (1 ml) is applied deep intramuscularly. Before use heat the contents of the vial to a temperature of 15–25 °C and shake well.Vaccina�on schedule:Primary vaccina�on: The first vaccina�on at the age of 6 months; the second vaccina�on 4 weeks later.

49

Vaccine against abor�ons cause EHV-1 provides par�al cross immunity against EHV- 4

COMPOSITIONAc�ve substances in one dose:Herpesvirus equorum inac�vatum (EHV-1)

1 min. 2.1 log10 VNIAdjuvant(s): Oil adjuvant (Montanide ISA 35 VG) 0.25 ml

Emulsion for injec�on. The vaccine is a oily liquid, creamy white, yellowish or pale pink colour, with easily shakeable sediment.


INDICATION For ac�ve immuniza�on of horses to reduce the occurrence of respiratory infec�on and clinical signs caused by equine herpesvirus (EHV-1) and to reduce the occurrence of abor�ons in pregnant mares caused by equine herpesvirus (EHV-1) infec�on.

Vaccina�on of pregnant mares: To reduce the incidence of abor�ons caused by equine herpesvirus infec�on one dose of the vaccine is administered to pregnant mares in the second month a�er ma�ng and then in the fi�h or sixth month and in the ninth month of pregnancy.

SHELF LIFEShelf-life of the veterinary medicinal product as packaged for sale: 18 months.Shelf-life a�er first opening the immediate packaging: 10 hours.

STORAGEStore in a refrigerator (2 °C – 8 °C). Protect from light. Store in a dry place.


BioEquin H, emulsion for injec�on for horses

3 Equine vaccines

Onset of ac�ve immunity: 14 days a�er primary vaccina�onDura�on of ac�ve immunity: 6 months a�er revaccina�on

Use during pregnancy, lacta�on or layCan be used during pregnancy.The safety of the veterinary medicinal product has not been established during lacta�on.

DOSAGEVaccine dose – 1 ml. The vaccine (1 ml) is applied deep intramuscularly.Before use heat the contents of the vial to a temperature of 15–25 °C and shake well.

Vaccina�on schedule

Primary vaccina�on:The first vaccina�on at the age of 6 months; the second vaccina�on 4 weeks later.

Revaccina�on: The first revaccina�on (third dose) is administered 3 months a�er the primary vaccina�on and next revaccina�on is carried out every 6 months.

Inac�vated vaccine against equine herpesvirus EHV-1

50

Safe toxoid vaccine for long-term protec�on against tetanus

COMPOSITIONAc�ve substance in one dose:Anatoxinum tetanicum purificatum RP ≥ 1Adjuvants:Algeldra� suspensio 0,1 mlExcipients:Thiomersalum 0,15 mg

Suspension for injec�on.

TARGET SPECIESHorses, ca�le, sheep, goats and dogs.

INDICATION For the ac�ve immuniza�on of horses, ca�le, sheep, goats and dogs against tetanus from 3 months of age.Onset of immunity: 14–21 days a�er basic vaccina�onDura�on of immunity: 2 years as a minimum, 4 years in horses

Basic vaccina�on:2 doses at an interval of 3 weeks for animals older than 3 months of age.Revaccina�on:Revaccina�on is recommended a�er two years, in horses a�er 4 years. In indicated cases another booster dose can be administered earlier.

SHELF-LIFE36 months

STORAGE Store in a refrigerator (2 °C – 8 °C). Keep in a dry room. Protect from light.

PACKAGE 2 × 1 ml, 10 × 1 ml, 20 × 1 ml

CLOTEID 4 suspension for injec�on

3 Equine vaccines

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONNo informa�on is available on the safety and efficacy of this vaccine when administered concurrently with other veterinary medicinal products. Decision about using this vaccine before or a�er any other veterinary medicinal product must be based on considera�on of individual cases.

DOSAGEThe vial contents should be shaken before use.Dose - 1 ml, regardless of age, weight and breed of an individual.Method of administra�on: intramuscular into the gluteal muscle. In horses, it is recommended to administer the product by the dry needle method, preferably into the gluteal muscle. In very restless horses, the product may be administered into the cervical or breast muscle.

Vaccine against tetanus

51

Effec�ve combina�on of three influenza an�gens

veterinary medicaments producer · 2017. 1. 27. · biobos respi 2 intranasal 38 biobos respi 3 39...

Documents